Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMM0XGL)

Drug Name
Idarubicin Drug Info
Synonyms
DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
42890
ChEBI ID
CHEMBL1117
CAS Number
CAS 58957-92-9
TTD Drug ID
D01XDL
VARIDT Drug ID
DR00386
INTEDE Drug ID
DR0852

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
p53 signaling pathway 2.51 0.00e+0 63/73 (86.3%) CDKN1A;DDB2;SESN1;...
Epstein-Barr virus infection 2.45 0.00e+0 189/202 (93.56%) CDKN1A;DDB2;RELB;...
Viral protein interaction with cytokine and cytokine re... 2.20 0.00e+0 84/100 (84%) CXCR4;TNFSF10;TNFRSF10B;...
Measles 2.20 0.00e+0 133/139 (95.68%) FAS;TP53;OAS1;...
Type I diabetes mellitus 2.18 0.00e+0 38/43 (88.37%) FAS;HLA-B;HLA-C;...
Herpes simplex virus 1 infection 2.18 0.00e+0 165/498 (33.13%) FAS;HLA-B;TAP1;...
Allograft rejection 2.11 0.00e+0 32/38 (84.21%) FAS;HLA-B;HLA-C;...
Graft-versus-host disease 2.10 0.00e+0 32/42 (76.19%) FAS;HLA-B;HLA-C;...
Influenza A 2.01 0.00e+0 156/172 (90.7%) FAS;TNFSF10;OAS1;...
Non-alcoholic fatty liver disease 2.00 0.00e+0 126/155 (81.29%) FAS;CASP7;JUN;...
Oxidative phosphorylation 1.99 0.00e+0 93/133 (69.92%) ATP5PF;NDUFB1;COX7B;...
Necroptosis 1.99 0.00e+0 113/159 (71.07%) FAS;TNFSF10;IRF9;...
NF-kappa B signaling pathway 1.96 8.37e-4 90/104 (86.54%) RELB;GADD45A;BLNK;...
Parkinson disease 1.94 7.77e-4 176/249 (70.68%) PPIF;TP53;SLC25A4;...
Viral myocarditis 1.92 2.18e-3 53/60 (88.33%) HLA-B;HLA-C;HLA-F;...
Autoimmune thyroid disease 1.91 2.04e-3 46/53 (86.79%) FAS;HLA-B;HLA-C;...
Apoptosis 1.89 5.12e-3 126/168 (75%) FAS;TNFSF10;GADD45A;...
Cytokine-cytokine receptor interaction 1.84 7.86e-3 246/295 (83.39%) FAS;CXCR4;TNFSF10;...
Toll-like receptor signaling pathway 1.82 8.59e-3 94/104 (90.38%) CXCL10;JUN;CCL5;...
RIG-I-like receptor signaling pathway 1.81 8.71e-3 64/70 (91.43%) ISG15;CXCL10;IFIH1;...
Other glycan degradation 1.80 9.33e-3 13/18 (72.22%) FUCA1;MAN2B2;HEXA;...
Kaposi sarcoma-associated herpesvirus infection 1.79 9.89e-3 172/193 (89.12%) CDKN1A;FAS;HLA-B;...
Inflammatory bowel disease 1.79 1.04e-2 58/65 (89.23%) MAF;JUN;STAT1;...
Basal cell carcinoma 1.77 1.18e-2 41/63 (65.08%) CDKN1A;DDB2;GADD45A;...
IL-17 signaling pathway 1.76 1.18e-2 84/94 (89.36%) CXCL10;S100A7;JUN;...
Histidine metabolism 1.74 1.30e-2 16/22 (72.73%) AOC1;ALDH9A1;MAOA;...
Huntington disease 1.73 1.49e-2 233/306 (76.14%) PPIF;TP53;SLC25A4;...
Hepatitis C 1.73 1.48e-2 139/157 (88.54%) CDKN1A;FAS;TP53;...
C-type lectin receptor signaling pathway 1.72 1.60e-2 93/104 (89.42%) RELB;IRF9;EGR2;...
Proteasome 1.69 1.60e-2 44/46 (95.65%) PSMB8;PSMB9;PSME2;...
Adherens junction -1.77 3.87e-2 63/71 (88.73%) RHOA;ACTN1;LMO7;...
Focal adhesion -1.83 3.45e-2 180/201 (89.55%) VWF;BIRC2;COL9A3;...
Steroid biosynthesis -1.90 1.23e-2 19/20 (95%) SOAT2;DHCR24;HSD17B7;...
Oocyte meiosis -1.99 1.38e-2 90/129 (69.77%) PRKACB;ANAPC10;MAPK14;...
Progesterone-mediated oocyte maturation -2.02 9.21e-3 75/100 (75%) PIK3CA;BRAF;PRKACB;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 0.08uM 6H
SK-ES-1 CVCL_0627 Homo sapiens 0.12uM - 1.11uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 12uM 6H, 24H, 48H
Brain
Glioblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-251 MG CVCL_0021 Homo sapiens 0.12uM - 12uM 24H
YH-13 CVCL_1800 Homo sapiens 0.12uM 24H
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 0.12uM - 1.11uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.002uM - 12uM 6H, 24H, 48H
MDA-MB-468 CVCL_0419 Homo sapiens 0.12uM - 12uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-474 CVCL_0179 Homo sapiens 0.12uM - 12uM 24H
T-47D CVCL_0553 Homo sapiens 0.12uM - 12uM 24H
ZR-75-1 CVCL_0588 Homo sapiens 0.12uM - 12uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 0.08uM 6H
GP2d CVCL_1234 Homo sapiens 0.12uM - 12uM 24H
HT-29 CVCL_0320 Homo sapiens 0.08uM - 12uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 0.08uM 6H
MDST8 CVCL_1400 Homo sapiens 0.08uM 6H
NCI-H508 CVCL_1561 Homo sapiens 0.08uM 6H
SNU-1040 CVCL_5001 Homo sapiens 0.08uM 6H
SNU-407 CVCL_5004 Homo sapiens 0.12uM - 12uM 24H
SNU-C4 CVCL_5008 Homo sapiens 0.08uM 6H
SNU-C5 CVCL_5009 Homo sapiens 0.08uM 6H
SW480 CVCL_0546 Homo sapiens 0.08uM 6H
SW620 CVCL_0547 Homo sapiens 0.08uM 6H
SW948 CVCL_0550 Homo sapiens 0.08uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 0.08uM 6H
HT115 CVCL_1294 Homo sapiens 0.08uM 6H
RKO CVCL_0504 Homo sapiens 0.08uM 6H
Embryonic stem cell
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WA09 (H9) Derived CVCL_9773 (WA09) Homo sapiens 0.12uM - 12uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 0.08uM - 12uM 6H, 24H
HEC-151 CVCL_2927 Homo sapiens 0.12uM - 12uM 24H
HEC-1-A CVCL_0293 Homo sapiens 0.12uM - 12uM 24H
HEC-251 CVCL_2928 Homo sapiens 0.12uM - 12uM 24H
HEC-265 CVCL_2929 Homo sapiens 0.12uM - 12uM 24H
SNG-M CVCL_1707 Homo sapiens 0.08uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 0.08uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 0.12uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.08uM - 10uM 6H, 24H
Renal cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RCC10RGB CVCL_1656 Homo sapiens 0.12uM - 1.11uM 24H
Rhabdoid tumor
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
G-401 CVCL_0270 Homo sapiens 0.12uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.08uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 0.12uM - 12uM 24H
JHH-7 CVCL_1322 Homo sapiens 0.12uM - 12uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.002uM - 12uM 6H, 24H, 48H
DV-90 CVCL_1184 Homo sapiens 0.08uM 6H
NCI-H1437 CVCL_1472 Homo sapiens 0.12uM - 12uM 24H
NCI-H1573 CVCL_1483 Homo sapiens 0.12uM - 12uM 24H
NCI-H838 CVCL_1594 Homo sapiens 0.12uM 24H
SK-LU-1 CVCL_0624 Homo sapiens 0.08uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 0.08uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 0.08uM 6H
T3M-10 CVCL_1729 Homo sapiens 0.08uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 0.12uM - 12uM 24H
HCC15 CVCL_1253 Homo sapiens 0.08uM 6H
HCC1588 CVCL_1263 Homo sapiens 0.12uM - 1.11uM 24H
HCC95 CVCL_1276 Homo sapiens 0.12uM - 12uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 0.08uM 6H
HCC515 CVCL_5134 Homo sapiens 0.08uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 0.08uM 6H
NCI-H2110 CVCL_1529 Homo sapiens 0.12uM - 1.11uM 24H
NCI-H2172 CVCL_1534 Homo sapiens 0.12uM - 1.11uM 24H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 0.08uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 0.08uM 6H
NCI-H841 CVCL_1595 Homo sapiens 0.12uM - 1.11uM 24H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 0.08uM 6H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 0.12uM - 1.11uM 24H
Oral cavity
Oral squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BICR 6 CVCL_1086 Homo sapiens 0.12uM - 1.11uM 24H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 0.08uM 6H
OV7 CVCL_1623 Homo sapiens 0.08uM 6H
OVK18 CVCL_1629 Homo sapiens 0.12uM - 1.11uM 24H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ES-2 CVCL_3509 Homo sapiens 0.12uM - 12uM 24H
OVTOKO CVCL_3114 Homo sapiens 0.12uM - 12uM 24H
RMG-I CVCL_1663 Homo sapiens 0.08uM 6H
Ovarian cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OAW 28 CVCL_1611 Homo sapiens 0.12uM - 12uM 24H
OC 316 CVCL_1615 Homo sapiens 0.12uM - 12uM 24H
Ovarian endometrioid carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TOV-112D CVCL_3612 Homo sapiens 0.12uM 24H
Ovarian granulosa cell tumor
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV434 CVCL_2010 Homo sapiens 0.12uM - 1.11uM 24H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 0.08uM 6H
RMUG-S CVCL_1666 Homo sapiens 0.08uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 0.08uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.12uM - 1.11uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.08uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 0.08uM 6H
PL-21 CVCL_2161 Homo sapiens 0.08uM 6H
SKM-1 CVCL_0010 Homo sapiens 0.08uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 0.08uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 0.12uM - 1.11uM 24H
LNCaP clone FGC CVCL_1379 Homo sapiens 0.12uM - 12uM 24H
PC-3 CVCL_0035 Homo sapiens 0.08uM - 12uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 0.08uM - 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.08uM - 12uM 6H, 24H
IGR-37 CVCL_1303 Homo sapiens 0.12uM - 1.11uM 24H
Mel-HO CVCL_1402 Homo sapiens 0.12uM - 12uM 24H
SH-4 CVCL_1692 Homo sapiens 0.12uM - 1.11uM 24H
SK-MEL-1 CVCL_0523 Homo sapiens 0.08uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 0.08uM 6H
SK-MEL-3 CVCL_0525 Homo sapiens 0.12uM - 12uM 24H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 0.08uM - 0.12uM 6H, 24H
MKN45 CVCL_0434 Homo sapiens 0.12uM - 12uM 24H
Gastric carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IM95 CVCL_1305 Homo sapiens 0.12uM - 12uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 0.12uM - 1.11uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 0.12uM - 1.11uM 24H